The report includes our forecast of Loss of Exclusivities
in US between 2025 through 2027.
Despite commoditization of the Para IV space, it still continues to attract all major generic manufacturers globally. As a result, ~$50 bn of sales will lose its exclusivity over next 3 years. Out of these total ~$50 bn in sales, ~50% will be exposed in 2025 alone – thanks to 3 biologics losing exclusivity in 2025.
While Indian companies continue to dominate this space, large international companies like Teva, Apotex, Mylan and Sandoz maintain its ranking among the top 10 generic companies with Para IV filings.
Interestingly, competitive intensity among Para IV Filers is reducing with the share of sole FTF holders rising significantly from 2025 to 2027.